Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2463)	1/7/2009 10:35:39 PM
From: Jibacoa	Respond to of 3722

CBST continues to hold to its nearterm UT that started after the " Reversal Day " on Oct10 bigcharts.marketwatch.com The stock was up 2.02% on volume below its ADV. On Monday it announced that it had submitted two INDs on Dec23 for CB-182,804, and CB-183,315 finance.yahoo.com Bernard

To: Jibacoa who wrote (2463)	9/11/2009 3:00:47 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ANSV has continued to have periodic 'interesting' spikes, albeit not as productive, or profitable, as the one from Dec15 to Dec 17 when the stock went from $0.08 to $1.49 in 2 days.<g> bigcharts.marketwatch.com Today the stock seems to be trying to start a move from the $0.25 level, and is still up 11.03% on volume of more than 630.900 > 2x its ADV . bigcharts.marketwatch.com Last month it announced that it had signed an agreement with a privately held company, Arcion Therapeutics, Inc. The merger will result in a public company with a portfolio of late-stage targeted pain therapeutics. The merger is expected to close in the 3rdQ and the stock will trade under the name of Arcion Therapeutics.After the closing ANSV will own 64% of the combined company. ANSV has a long history of capital losses.The proposed merger creates a synergistic company with a pipeline comprised of late-stage programs that address markets with unmet needs, such as neuropathic pain, moderate-to-severe osteoarthritis and post-operative pain. ANSV's Adlea (capsaicin) for post-operative pain completed two PIIIs last year, and Arcion's ARC-4558 (0.1% topical clonidine gel) is a PIIb for painful diabetic neuropathy.It also has ARC-2022, a topical drug for post-herpetic neuralgia, which is in preclinical development.<g> In spite of its long history of losses, it seems ANSV is worth of keeping on a 'watch list', as it most likely will continue to have very profitable spikes, but don't expect for it to be able to close any of its Nov 2004 DG in the near future.<g> I will keep a temporary 'target' at $1 <g> bigcharts.marketwatch.com Bernard